All News

David Olson, PhD, the chief innovation officer, head of scientific advisory board, and co-founder of delix therapeutics and an associate professor at University of California, Davis, discusses psychedelics and other psychoplastogens in the treatment of brain and mental health disorders.

The health of a pharmacy business is under attack from many directions, but retail pharmacies can take steps to alleviate some of this pressure to improve the health of their business.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses next steps in the research assessing zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.

Bladder cancer risk increases with age and is more common among men than women.

Study suggests that emergency physicians prescribe naloxone to patients who overdose.

Common triggers for atrial fibrillation include alcohol, caffeine, and less sleep.

Flatfeet develop after an injury or from the simple wear-and-tear stresses of age.

The emergency use authorization is based on data from the EPIC-HR trial, which showed that the drug significantly reduced the risk of hospitalization or death compared with the placebo.

The drug is available in both oral suspension and tablet dosage forms for use in individuals aged 18 years or younger.

The agency’s approval follows trial results demonstrating the superior efficacy of the cabotegravir long-acting injectable to a daily oral PrEP option in reducing the risk of infection.

Ronald T. Piervincenzi, PhD, CEO of US Pharmacopeia, explains how pharmacists and USP came together in 2021 to work harder than ever before, as well as what can be done now to prepare for the next health crisis.

Crestor is indicated for the treatment of patients with primary hyperlipidemia and mixed dyslipidemia.

TXNIP inhibition could prevent beta cell loss and protect beta cell function to potentially contribute to diabetes management and its complications.

Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, discusses the results for all of the trial endpoints assessing daratumumab, carfilzomib, lenalidomide, and dexamethasone for patients with newly diagnosed multiple myeloma.

Pharmacists play an important role in educating patients and other health care practitioners on the signs and symptoms of C. difficile infection.

Paying close attention to the pharmacy’s operational and financial success does not have to come at the expense of quality patient care.

The prescription-only crofelemer delayed-release tablets were developed using a sustainable, plant-based formula.

Lotrimin is indicated for the treatment of several common skin infections, such as athlete's foot, jock itch, and ringworm.

Jacob D. Soumerai, MD, of Harvard Medical School and Massachusetts General Hospital, discusses trial results showing the safety and efficacy of zanubrutinib, obinutuzumab, and venetoclax in the treatment of previously untreated chronic lymphocytic leukemia.

Holistic wellness and helping patients manage the toxins in their outside life are just a few of the focuses at Wobbly Arrow Wellness.

The data highlight a new role for pregnancy-associated plasma protein A, known as PAPP-A, in gestational diabetes, with translational potential as both a diagnostic tool and therapeutic target, according to the investigators.

Modern technology is crucial to the provision of home infusions.

Immunocompromised individuals are at a higher risk of developing severe symptoms and dying from COVID-19.

Investigators found that an additional hour of sleep correlated with a 26% decrease in an infant’s risk of being overweight.

Symptoms of fibrous dysplasia include bone pain, swelling, bone deformity, bone and fractures.

Terrasil Shingles Skincare helps to alleviate pain, itching, burning, and irritation associated with shingles.

Vraylar is an atypical antipsychotic indicated for the treatment of adult patients with schizophrenia and for manic, mixed, or depressive episodes for patients with bipolar I disorder.

Company is the first to file an ANDA referencing Vasostrict, which had total US sales of $786 million in 2020.